Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11213634 | 0.80 | TSHR (0.44) | PPARDTSHRTP53TDP1MAPT | |
| SCHEMBL25758493 | 0.78 | PPARD (0.43) | PPARDTSHRUGT2B7 | |
| SCHEMBL30186533 | 0.74 | PPARD (0.39) | PPARDTSHR | |
| SCHEMBL11221537 | 0.73 | TSHR (0.41) | PPARDTSHRTP53TDP1MAPT | |
| SCHEMBL3313657 | 0.71 | PPARD (0.70) | PPARDTSHRTP53TDP1 | |
| SCHEMBL12154630 | 0.71 | PPARD (0.40) | PPARDTSHR | |
| SCHEMBL12154629 | 0.71 | PPARD (0.40) | PPARDTSHR | |
| SCHEMBL30186686 | 0.71 | PPARD (0.40) | PPARDTSHRENPP2LPAR2 | |
| SCHEMBL23881696 | 0.70 | TYMS (0.39) | LPAR2 | |
| SCHEMBL24392559 | 0.69 | PPARD (0.45) | PPARDTSHRTP53TDP1UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4406950-A2 | LFA-1 INHIBITOR AND POLYMORPH THEREOF | Bausch + Lomb Ireland Limited (IE) | 2024-07-31 | — | — | EP | disclosed |
| EP-3715345-B1 | PREPARATION OF LFA-1 INHIBITOR | NOVARTIS AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3715345-A2 | PREPARATION OF LFA-1 INHIBITOR AND POLYMORPH THEREOF | Novartis AG (CH) | 2020-09-30 | — | — | EP | disclosed |
| US-20200087287-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE BIOSCIENCE INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20180251452-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9890141-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890141-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20140031387-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARcode Bioscience, Inc. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARcode Bioscience, Inc. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARcode Bioscience, Inc. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2011050175-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE CORPORATION (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087287-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | PPARD 1918/4885TSHR 3522/4885TP53 1224/4885 |
| US-20140031387-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | PPARD 1816/4885TSHR 3111/4885TP53 1021/4885 |
| US-20180251452-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | PPARD 1918/4885TSHR 3522/4885TP53 1224/4885 |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | PPARD 1918/4885TSHR 3522/4885TP53 1224/4885 |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | PPARD 1918/4885TSHR 3522/4885TP53 1224/4885 |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | ITGB1, ITGA1, VCAM1 | PPARD 1816/4885TSHR 3111/4885TP53 1021/4885 |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | PPARD 1816/4885TSHR 3111/4885TP53 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.